Therapeutic plasma exchange for steroid unresponsive multiple sclerosis relapses - A long-term follow-up observation including 35 patients;Plasmapherese in der eskalationstherapie der multiplen sklerose: Verlaufsbeobachtung an 35 patienten

Aktuelle Neurologie

Volumn 36, Issue 3, 2009, Pages 105-110

  Schroder A ^a   Fischer, M ^a   Meyer, C ^a   Ellrichmann, G ^a   Thone J ^a   Linker, R A ^a   Chan, A ^a   Gold, Ralf ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Escalating immunotherapy; Immunoadsorption; Long term follow up observation

Indexed keywords

AZATHIOPRINE; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; RECOMBINANT BETA INTERFERON; STEROID;

ADULT; ARTICLE; CATHETER INFECTION; CLINICAL ARTICLE; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; HUMAN; IMMUNOADSORPTION; MALE; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PLASMAPHERESIS; SEPSIS; SYMPTOM; THERAPY EFFECT; VEIN THROMBOSIS;

EID: 67649574260     PISSN: 03024350     EISSN: 14389428     Source Type: Journal    
DOI: 10.1055/s-0028-1090231     Document Type: Article

References (17)

1. Keegan M, Konig F, McClelland R et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366: 579-582
2. Weinshenker BG, O'Brien PC, Petterson TM et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886
3. Keegan M, Pineda AA, McClelland RL et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58: 43-146
4. Schilling S, Linker RA, Konig FB et al. [Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients]. Der Nervenarzt 2006; 77: 430-438
5. Ruprecht K, Klinker E, Dintelmann T et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004; 63: 1081-1083
6. Bruck W, Neubert K, Berger T et al. Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination-possible markers for antibody-mediated process. Mult Scler 2001; 7: 173-177
7. Haupts MR, Schimrigk SK, Brune N et al. Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology. J Neurol 2008; 255: 1272-1273
8. Beck RW, Cleary PA, Anderson MMJ et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group [see comments]. N Engl J Med 1992; 326: 581-588
9. Beck RW, Cleary PA, Trobe JD et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329: 1764-1769
10. Palm M, Behm E, Schmitt E et al. Immunoadsorption and plasma exchange in multiple sclerosis: complement and plasma protein behaviour. Biomater Artif Cells Immobilization Biotechnol 1991; 19: 283-296
11. Hosokawa S, Oyamaguchi A, Yoshida O. Successful immunoadsorption with membrane plasmapheresis for multiple sclerosis. ASAIO Trans 1989; 35: 576-577
12. Gold R, Krenzer M, Klinker E, Mansouri B et al. Efficacy and safety of immunoadsorption vs plasmapheresis vs combination for treatment of myasthenic crisis: comparative retrospective study on 72 patients. Neurology 2008; 70 (Suppl. 1): A427
13. Zhou D, Srivastava R, Nessler S et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Nat Acad Sci 2006; 03: 19057-19062
14. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210-218
15. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005; 139: 152-158
16. Bar-Or A, Calabresi PA, Arnold D et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63: 395-400
17. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688